- £1.92bn
- £993.52m
- $630.20m
- 17
- 44
- 72
- 37
RCS - Hutchmed China Ltd - HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Planned Enrollment of FRESCO-2
AnnouncementREG - Hutchmed China Ltd - Updated NRDL to include ELUNATE and SULANDA
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and AZ Initiate SACHI Phase 3 Trial
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present Clinical Data at ASH
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and AZ Initiate SAMETA Global P3 Trial
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase III Trial of HMPL-523
AnnouncementREG - Hutchmed China Ltd - Grant of Awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Presentations at CSCO 2021
AnnouncementRCS - Hutchmed China Ltd - Closure of Non-Core OTC Joint Venture Divestment
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase III Trial SURTORI-01
AnnouncementRCS - Hutchmed China Ltd - Japan Bridging Study For Surufatinib Initiated
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation for Amdizalisib
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and AZ Initiate Phase III Trial in China
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present Clinical Data at ESMO
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Shares Included in Stock Connect Programs
Announcement